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ABSTRACT
Introduction: Pancreatic cancer is the fourth leading cause of cancer-related death
among males and females in the United States. Sel-1-like (SEL1L) is a putative tumor
suppressor gene that is downregulated in a significant proportion of human pancreatic
ductal adenocarcinoma (PDAC). It was hypothesized that SEL1L expression could be
down-modulated by somatic mutation, loss of heterozygosity (LOH), CpG island
hypermethylation and/or aberrantly expressed microRNAs (miRNAs).
Material and methods: In 42 PDAC tumors, the SEL1L coding region was amplified
using reverse transcription polymerase chain reaction (RT-PCR), and analyzed by
agarose gel electrophoresis and sequenced to search for mutations. Using fluorescent
fragment analysis, two intragenic microsatellites in the SEL1L gene region were
examined to detect LOH in a total of 73 pairs of PDAC tumors and normal-appearing
adjacent tissues. Bisulfite DNA sequencing was performed to determine the
methylation status of the SEL1L promoter in 41 PDAC tumors and 6 PDAC cell lines.
Using real-time quantitative PCR, the expression levels of SEL1L mRNA and 7
aberrantly upregulated miRNAs that potentially target SEL1L were assessed in 42
PDAC tumor and normal pairs. Statistical methods were applied to evaluate the
iv

correlation between SEL1L mRNA and the miRNAs. Further the interaction was
determined by functional analysis using a molecular biological approach.
Results: No mutations were detected in the SEL1L coding region. More than 50% of
the samples displayed abnormally alternate or aberrant spliced transcripts of SEL1L.
About 14.5% of the tumors displayed LOH at the CAR/CAL microsatellite locus and
10.7% at the RepIN20 microsatellite locus. However, the presence of LOH did not
show significant association with SEL1L downregulation. No methylation was
observed in the SEL1L promoter. Statistical analysis showed that SEL1L mRNA
expression levels significantly and inversely correlated with the expression of hsa-mir143, hsa-mir-155, and hsa-mir-223. Functional analysis indicated that hsa-mir-155
acted as a suppressor of SEL1L in PL18 and MDAPanc3 PDAC cell lines.
Discussion: Evidence from these studies suggested that SEL1L was possibly
downregulated by aberrantly upregulated miRNAs in PDAC. Future studies should be
directed towards developing a better understanding of the mechanisms for generation
of aberrant SEL1L transcripts, and further analysis of miRNAs that may downregulate
SEL1L.
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BACKGROUND

1. Pancreatic cancer
The pancreas is an organ which has both endocrine and exocrine components.
The endocrine component secretes hormones into the blood. Microscopically, the
endocrine pancreas is made of cell clusters called islets of Langerhans which consist
of five types of cells: alpha cells, beta cells, delta cells, PP cells and epsilon cells.
Acinar cells of the exocrine pancreas produce and secret digestive enzymes and
pancreatic juice (an alkaline fluid) into the small intestines through the exocrine ducts.
Pancreatic cancer usually arises from the exocrine portion of pancreas [1].
In the United States, pancreatic cancer is the fourth leading cause of cancerrelated death among males and females. “The American Cancer Society's most recent
estimates for pancreatic cancer in the United States for 2010 are: about 43,140 new
cases (21,370 men and 21,770 women), and about 36,800 deaths (18,770 men and
18,030 women). The lifetime risk for developing pancreatic cancer is about 1 in 71
(1.41%), which is about the same for both men and women.” Tobacco smoking,
family history of pancreatic cancer, personal history of pancreatitis, diabetes and
obesity are all commonly recognized risk factors for this type of cancer [2]. Since the
symptoms of pancreatic cancer are non-specific and varied, usually by the time it is
diagnosed local or distant metastasis has already occurred. Prognosis for this disease is
very poor with a median survival time of less than 6 months for all patients diagnosed
with this disease, and the overall 5-year survival is only 6% [3]. The most common
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form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which
accounts for >75% of all pancreatic tumors [4].
Histologically, PDAC is an invasive malignant epithelial neoplasm with no
predominant component of any of the other carcinoma types. The appearance and
arrangement of the PDAC cells present a duct-like structure instead of the
predominant acinar cell structure seen in normal pancreas. “The degree of gland (duct)
formation can vary from well-formed glands, to partially formed glands, to focal
intracellular mucin production by poorly oriented cells infiltrating singly, to solid
sheets of neoplastic cells.” [5] Although PDAC has a ductal morphology, there is no
formal proof demonstrating that it originates from the ductal compartment.
Acinar-to-ductal metaplasia has been implicated in the generation of pancreatic
cancer precursor lesions known as pancreatic intraepithelial neoplasia (PanIN) [6-8].
Metaplasia is defined as a predominant cell type in a tissue being replaced by another
cell type. There is evidence for at least two pathways for development of acinar-toductal metaplasia. In the first, abnormal acinar cells transdifferentiate to ductal cells
and then proliferate. In the second, ductal cells proliferate and the abnormal acinar
cells undergo apoptosis.
Animal models have been used to study the process of acinar-to-ductal
metaplasia. Guerra et al. selectively expressed K-RASG12V in mice embryonic cells of
the acinar/centroacinar lineage and observed the formation of PanIN lesions and
invasive PDAC [9]. Similarly, Habbe et al. reported that knockin of the K-RASG12D
allele in mature acinar cells of adult mice resulted in spontaneous induction of murine
PanIN lesions of all histological grades [10]. By performing murine pancreatic
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epithelial explants, Dr. Leach’s group showed spontaneous acinar-to-ductal metaplasia
in response to EGFR signaling. The transdifferentiated cells simultaneously express
both acinar and ductal markers [11].
In summary, all these models provided evidence that the genetic signature of
pancreatic cancer involves genetic alterations in PanIN lesions that may induce acinarto-ductal cell transdifferentiation and further development into PDAC.

2. Genetic alterations in the pathogenesis of PDAC
Many allelic alterations have been seen in PDAC, including losses of 1p, 9p,
12q, 17p, 18q and gain of 20q [12-18]. Several of these have been demonstrated to be
involved in the progression of PDAC. The early genetic changes include the aberrant
activation of the epidermal growth factor receptor (EGFR), erbB2 (HER2), v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (K-Ras), and the inactivation of Cyclindependent kinase inhibitor 2A (CDKN2A/p16-INK4A) and alternative reading frames
of the INK4A (ARF) tumor suppressor proteins [19-21]. Loss of two tumor
suppressors, TP53 (p53) and BRCA2, frequently occur in the progression of the
pancreatic intraepithelial neoplastic (PanIN) lesions. Loss of SMAD4/DPC4 function
occurs at later stages [19, 20]. Overexpression of various components of Hedgehog
(Hh) signaling including Shh and Ihh also have been seen in PanIN lesions as well as
invasive PDAC [22-24]. An oncogenic serine/threonine kinase, AURKA, also showed
overexpression in PDAC [25, 26]. The 9p21 region harbors the p16-INK4A gene; the
17q13 region harbors the p53 gene; the SMAD4 gene is located on chromosome 18q21
and AURKA maps to chromosome 20q13. Therefore, allelic loss or gain may explain
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some of the gene expression alterations. Many signaling pathways can be affected by
the above genetic abnormalities, such as the EGFR signaling pathway, the Ras
signaling pathway, the transforming growth factor-beta (TGFβ) signaling pathway, as
well as the Hedgehog (Hh) pathway and the Wnt–β-catenin cascades [27].
However, all the above genetic alterations have also been observed in many
other kinds of cancers, so unfortunately none of these serve as PDAC tumor specific
biomarkers.

3. SEL1L gene and PDAC
Seven genes were identified in Dr. Killary’s laboratory, which were found to
be differentially expressed in PDAC across three platforms. Products of these genes
could serve as candidate biomarkers for PDAC [28]. One of the genes, SEL1L, has
been shown to be abundantly expressed specifically in pancreatic tissues from healthy
adult humans [29, 30]. Biunno et al. reported that SEL1L messenger RNA (mRNA)
was not detected in 17% of PDAC tumors by reverse-transcription polymerase chain
reaction (RT-PCR) [29]. Downmodulation or absence of SEL1L protein has been seen
in 36% of human PDAC cases by immunohistochemistry. Immunohistochemical
staining revealed that SEL1L protein is highly expressed in normal pancreatic acinar
and islet cells, whereas it is not expressed in normal ductal cells [31]. Therefore, a
question was raised that whether SEL1L downregulation was caused by the difference
in cell types between normal pancreas and PDAC tumors. To answer this question,
understanding the cellular origin of PDAC is a key. Acinar to ductal
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transdifferentiation in some model systems suggests that acinar cells may be the cell of
origin, and this may explain why SEL1L is expressed in some PDACs.
SEL1L has been shown to modulate the expression of certain cancer-related
proteins. In C. elegans, sel-1 has been identified as a negative regulator of the lin12/Notch family oncoproteins, lin-12 and glp-1. This is likely through its function in
protein degradation [32, 33]. Overexpression of SEL1L in stably transfected PDAC
cells and in nude mice caused a decrease in the aggressive behavior of the tumor cells,
suggesting that SEL1L plays a tumor-suppressive role in the progression of PDAC
[31]. Overexpression of SEL1L in PDAC cells also showed a significant increase in
the expression level of the tumor suppressors Smad4, activin A, TIMP1, TIMP2, and
PTEN, suggesting an interaction of SEL1L with the TGFβ and PTEN signaling
pathways [31, 34].

4. SEL1L gene and SEL1L protein
The homo sapiens SEL1L gene is located on chromosome 14q24.3-q31 with a
length of 60967 base pairs (bp). It consists of 21 exons and the corresponding full
length mRNA contains 6593 bp and the coding region is 2385 bp long. According to
the gene annotations in the AceView database, National Center for Biotechnology
Information (NCBI), the SEL1L gene produces 10 different transcripts that potentially
encode 8 different isoforms [35].
At the N terminus of the SEL1L protein, there is an XXRR-like ER
(endoplasmic reticulum) membrane retention signal, and a proline, glutamic acid,
serine, and threonine peptide (PEST) sequence which is known to target proteins for
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rapid degradation. The SEL1L protein also contains a fibronectin type II domain
which is a collagen-binding domain, three SEL-1-like sequence clusters in tandem
which are predicted to function in protein-protein interaction, one highly conserved
Hrd3-like motif which also has predicted function in protein binding, one
transmembrane domain, and one proline-rich tail which may bring proteins together.
Hrd3 is a protein of the ER membrane that plays a central role in ER associated
protein degradation (ERAD). The Hrd3 protein motif is shared with several other
proteins [36, 37]. From the protein structure, SEL1L is predicted to be an ER
membrane protein with functions of protein-protein interaction and protein
degradation. It has been reported that the region of SEL1L spanning amino acids 659
to 794 containing the Hrd3-like motif, the transmembrane domain and the proline-rich
tail is required for tumor growth inhibition [38].

5. SEL1L and UPR/ERAD pathway
The human homolog of SEL1L has been recognized as a component of the
“unfolded protein response/endoplasmic reticulum associated protein degradation
(UPR/ERAD) pathway” [36, 39, 40]. The pancreas is an organ that produces many
important proteins, such as insulin, glucagon and digestive enzymes [1]. Endoplasmic
reticulum is an organelle found in all eukaryotic cells which functions in protein
translation, folding, export and secretion [41]. Therefore, the ER is a critical organelle
for synthesis and secretion of the many proteins made in the pancreas.
Certain pharmacological or physiological conditions such as hypoxia, redox or
glucose starvation, may lead to an accumulation of unfolded or misfolded proteins in
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the lumen of the ER and cause ER stress. The UPR/ERAD pathway is triggered in
response to the stress and induces the activation of several additional signaling
pathways to promote long-term stress adaptation or apoptotic cell death [42].
Figure 1 shows a simplified version of the URP/ERAD pathway. The primary
function of this pathway is to maintain ER homeostasis and produce cell survival after
stress. When this pathway is activated, the ER chaperone glucose-regulated protein 78
(GRP78), the serine/threonine kinase Akt, the nuclear factor NF-κB, and the antiapoptosis factor Bcl-2/xL are induced [43-49]. Consequently, cell proliferation and
angiogenesis are promoted. Simultaneously, the E3 ubiquitin-protein ligase HMGCoA reductase degradation protein 1 (HRD1) and SEL1L are also induced by the ER
stress. SEL1L interacts with and stabilizes HRD1, and also recognizes misfolded
proteins and transfers them into the cytosol for degradation [37-39]. On the other
hand, when the accumulated unfolded proteins exceed a threshold above which the ER
stress can no longer be controlled, the cell becomes committed to apoptosis through
another part of the UPR pathway. Gadd153/CHOP is the dominant ER chaperone that
is induced [50]. Caspase-4, a caspase responding only to ER stress and not to other
signals, is activated [51]. When SEL1L expression was knocked down in mouse
pancreatic β-cells, a decrease in cell growth was observed. This may be through
activation of the apoptosis pathway described above [52].
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Figure 1. Unfolded protein response/endoplasmic reticulum associated protein
degradation (UPR/ERAD) pathway. Green: survival pathway; pink: apoptosis
pathway.
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6. The goals of this study
So far neither mutations nor genomic alterations have been reported for SEL1L
which is a putative tumor suppressor in PDAC. The goals of this study were to
investigate the molecular mechanisms of SEL1L downregulation, and to better
understand the role of SEL1L in the pathogenesis of PDAC. I hypothesized that
SEL1L expression could be down-modulated by somatic mutation, loss of
heterozygosity (LOH), CpG island hypermethylation and/or aberrantly expressed
microRNAs (miRNAs). Results from this study provide a better understanding of the
abnormalities of the SEL1L gene in PDAC, which may lead to the discovery of PDAC
tumor specific biomarkers or the development of new prevention and treatment
strategies for this dismal disease.

9

Chapter 1

SEL1L Gene Mutation Study
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1.1 Introduction
Due to genetic instability, cancer cells often carry somatic mutations in either
tumor suppressor genes or oncogenes. Somatic mutations occurring at the splice sites
or exonic splicing enhancers may cause aberrant transcription, and may lead to the
translation of aberrant proteins. Mutations occurring at the coding region of a gene
may also produce aberrant proteins, which may influence the function of the gene.
Mutations in some predominant cancer-related genes have been frequently reported in
PDAC tumors. For example, Kras mutations are some of the earliest events in the
tumorigenesis of PDAC, which have been detected in 90% of PDACs with most of the
mutations occurring at codon 12, 13, and 61; loss of the p53 gene often occurs later in
the development of pancreatic neoplasia, generally by missense alterations of the
DNA-binding domain in more than 50% of PDACs [18-20].
So far, only one study of SEL1L gene alterations in PDAC has been conducted.
In this study Southern blotting was performed on 17 neoplastic cases, but no gross
genomic alterations were observed [28]. The Southern blotting method uses probe
hybridization to identify a restriction fragment of a gene. However, in this report the
authors did not give the exact region that they examined, and apparently they did not
examine the whole gene region of SEL1L. Their results might not give an accurate
conclusion, and it is still important to determine if somatic mutations are present in the
SEL1L gene. Therefore, I chose to examine SEL1L for mutation in PDAC samples.

11

1.2 Materials and Methods

Materials
PDAC tumors and the matched normal-appearing adjacent pancreatic tissue
specimens were collected from surgical resections performed at The University of
Texas M. D. Anderson Cancer Center (UTMDACC) before patients were treated with
chemotherapy or radiotherapy. The identification of normal adjacent tissue was based
on microscopical observations from the pathologist analyzing the tissue. All the
tissues were stored in -80ºC freezers prior to RNA/DNA extraction. A total of 42
tumor/normal pairs were examined in this study. A quality check of integrity with the
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) indicated that the RNA
samples did not display degradation.

Extraction of RNA and DNA
Total RNA was extracted using the miRNeasy Mini Kit according to the
manufacturer’s instructions (Qiagen, Valencia, CA). DNA was extracted from the
inter-phase and phenol phase after RNA isolation. The isolation procedures followed
the TRIzol Reagent protocol (Invitrogen, Carlsbad, CA). DNA and RNA
concentrations were measured with a NanoDrop spectrophotometer (Thermo
Scientific, Wilmington, DE).

Reverse transcription polymerase chain reaction (RT-PCR) and sequencing

12

The High Capacity cDNA Reverse Transcription Kits (Applied Biosystems,
Foster City, CA) were used for complementary DNA (cDNA) synthesis. The
conversion to cDNA started from 1ug of total RNA in a single 20µL reaction using
random primers. To amplify the cDNA with high fidelity, three sets of primers were
used for the entire coding region of SEL1L, and the RT-PCR products overlapped one
another by about 100 bp.
The SELmRNA-1 primer set generates a product of 934 bp which extends
from SEL1L exon 1 to 7. SELmRNA-2 generates a 972 bp product which is from exon
6 to 17. SELmRNA-3 amplifies exon 16 to 21 and the product size is 987 bp.
Sequences and locations of the primers were shown in Figure 2. The reactions were
carried out in a final volume of 30 uL of a mixture containing 2µL of cDNA, 10 pmol
of each primer, deoxynucleotide triphosphates (dNTP, each at 0.25 mM), KCl (50
mM), MgCl2 (1.5 mM), Tris-HCl (10 mM, pH 8.3), and 1 unit of AmpliTaq Gold
DNA polymerase (Applied Biosystems). The same thermal cycling conditions were
applied to all 3 reactions: denaturation at 95°C for 5 minutes for 1 cycle, followed by
40 cycles at 95°C for 45 seconds, 56°C for 45 seconds, 72°C for 45 seconds, and then
an extension of 72°C for 7 minutes. A 5 uL aliquot of the RT-PCR products was run
through 1% agarose gel (Phenix Research Product, Candler, NC) using 100 bp DNA
ladder as a molecular weight marker (Invitrogen). The remainder of the products were
purified with QIAquick PCR Purification Kit (Qiagen), and then sequenced in the
DNA Analysis Facility at UTMDACC using ABI PRISM 3730 DNA sequencers
(Applied Biosystems).
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A.

B.

Figure 2. Sequences and locations of the primers for SEL1L coding region
mutation study. The rectangular boxes in figure B represent the exons in SEL1L
cDNA. Translation start site and stop site were indicated. F1 and R1 indicate the
locations of forward and reverse primers of SELmRNA-1; F2 and R2 are SELmRNA2; F3 and R3 are SELmRNA-3.
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1.3 Results

Altered SEL1L transcripts in PDAC tumors and paired normal-appearing adjacent
tissues
When reverse-transcribed mRNAs were amplified using the SELmRNA-1
primer sets, agarose gel electrophoresis revealed that in addition to the predicted RTPCR products, some weaker products with smaller sizes were present. These smaller
products were observed in both PDAC tumor tissues and normal-appearing adjacent
tissues. This phenomenon was not observed when the cDNAs were amplified using
the SELmRNA-2 and SELmRNA-3 primer sets. The representative results from 7
tumor/normal pairs are shown in Figure 3. When the RT-PCR was repeated using the
SELmRNA-1 primers, although additional products were observed again, different
patterns of products were present. From the results of two independent RT-PCR
amplifications, additional products were identified in more than half of the samples.
Because most of the unexpected small products had much lower intensities,
nucleotide sequence analysis usually displayed only the sequence of the
predominating normal products. However, in a few of the samples one smaller product
showed competitive intensity compared to the expected product. Sequencing
chromatograms of these samples showed identifiable double peaks, so that the
sequence of both products could be analyzed. Figure 4 shows such a chromatogram
displaying the out of phased sequence indicating deletions.

15

Figure 3. Agarose gel electrophoresis of representative RT-PCR products of
SEL1L coding region. M, marker. T, PDAC tumor. N, normal-appearing pancreatic
tissue. Specimens from the same patient have the same number. Names of primer sets
are noted at the right.
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Figure 4. A sequencing chromatogram displays double peaks. The RT-PCR
products of a PDAC tumor sample were produced using SELmRNA-1 primers. The
out-of-phase sequence starts at position 157 and extends to position 360, indicating the
existence of two products in this sample.
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Figure 5 shows SEL1L mRNA RT-PCR products from 5 representative
samples. In Figure 5A, using agarose gel electrophoresis, multiple different products
with competitive intensities can be identified in the 5 samples. Figure 5B
schematically presents a diagram of the sequencing results of the full-length (FL)
normal product and the small aberrant products. The 497bp fragment in sample 1
skipped exons 4, 5, and 6 and potentially encodes a truncated protein of 125 amino
acids (aa). In sample 2, exon 3 was skipped and a stop codon was introduced in exon 4
so that a protein of 37 aa could be generated. The sequence of the 871-bp fragment in
sample 3 showed that 63 bp from the beginning of exon 4 was spliced through a novel
AG splice acceptor site. The predicted amino acid sequence is in-frame with 21 aa
deleted. In the 293-bp fragment of sample 4, a non-conserved donor site in exon 2
was joined to a non-conserved acceptor site in exon 6. Both the donor and acceptor
contain a 7-base sequence of AGGCAGC. The frameshift of this fragment would
produce a 32-aa truncated protein. Similar aberrant splicing happened in sample 5 as
was seen in sample 4. The splicing donor site in sample 5 was the same as in sample
4, but the acceptor site was at a different location in exon 6. A 46-aa protein would be
encoded.
These sequencing results indicated that the smaller products arose as a result of
mis-splicing of the SEL1L pre-mRNA, but none of these products are included in the
NCBI transcription annotation database (AceView). This database is supposed to
provide a comprehensive and non-redundant sequence representation of all public
mRNA sequences [33]. Commonly, mis-splicing occurring at intron-exon boundaries
is referred to as alternate splicing; and splicing occurring at cryptic splice sites (within
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intron or exon) is referred to as aberrant splicing. Here, samples 1, 2, and 3 showed
alternate splicing, and samples 4 and 5 showed aberrant splicing.
Mis-splicing could be caused by mutations at the splicing sites. Therefore, of
the 5 samples in Figure 5, polymerase chain reaction (PCR) products of the genomic
sequences flanking the intron-exon boundaries and the non-conserved splicing sites
were generated. No mutations were detected (data not shown here), indicating that the
alteration of SEL1L splicing was not caused by genomic mutations.

Mutation is not detected in the SEL1L coding region
The sequence of the whole SEL1L coding region was determined for cDNA
generated from 42 PDAC tumor samples and compared to the SEL1L coding sequence
reported in Genbank using the BLAST computer algorithm [53], but no mutations
were detected in any of them. Several single nucleotide polymorphisms (SNPs) were
identified in the sequences that have been listed in the NCBI dbSNP database,
including rs11499034 located in exon 4 in 1 sample, rs11851475 in exon 17 in 1
sample, and rs1051193 in exon 20 in 2 samples. The frequencies of these SNPs were
close to the reported frequencies in the NCBI database in the normal population of
Caucasians, indicating that these SNPs are normally present.
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Figure 5. Alteration of SELmRNA-1 RT-PCR products in 5 PDAC tumors.
A. Agarose gel electrophoresis. M, marker. B. Schematic diagram of the smaller
products in relation to the full-length fragment. FL, full-length (expected product). A
broken line in an exon indicates an incomplete exon. Each rectangular box represents
one exon. Arrows indicate the locations of stop codon for protein translation. RT-PCR
product sizes are noted at the right.
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1.4 Discussion
In this study, I investigated whether genetic mutations exist in the pancreasspecific putative tumor suppressor gene SEL1L in PDAC cases, and whether mutations
are the cause of SEL1L downregulation. By amplifying and sequencing the coding
region of SEL1L in 42 pairs of PDAC tumors and normal adjacent tissues, no
mutations were detected; interestingly, however, unexpected altered splice forms of
SEL1L pre-mRNA were observed.
Sequencing results revealed that these RT-PCR products were true SEL1L
transcripts that were not generated from PCR artifacts or wrong priming. The
unexpected splicing products that were observed were different from the normal
SEL1L alternate transcripts that are annotated in the NCBI database. These unexpected
SEL1L RT-PCR products had weak intensities on agarose gels, and the exact patterns
were not reproducible. This lack of reproducibility is likely due to a low abundance of
any given aberrant splice product.
The formations of the alternate/aberrant splice products shown in Figure 5
suggest that the splicing alterations of SEL1L most likely occur between exon 2 to
exon 6. The protein sequence corresponding to this region involves a PEST sequence,
a Fibronectin Type II (FNII) domain, and a SEL-1-like repeat. The predicted truncated
SEL1L proteins missing these specific domains would lose their function in protein
modulation. It is also possible that the dysfunctional proteins interrupt the tumorsuppressor function of normal SEL1L protein through a competition for target protein
binding.
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The same mis-splicing phenomena have been previously reported in other
tumor suppressor genes in various cancers, such as tumor susceptibility gene 101
(TSG101) in breast and lung cancer [54, 55], Mdm2 p53 binding protein homolog
(MDM2) in ovarian, bladder, and breast cancer [56-58], and fragile histidine triad gene
(FHIT) in breast, head and neck, and lung cancers [59-61]. In PDACs, abnormal
transcripts have been observed in cholecystokinin-B/gastrin receptor (CCKBR) [62]
and Mucin type 4 (MUC4) [63].
Similar to what has been seen for the TSG101, MDM2 and FHIT genes,
abnormal products in normal-appearing tissues adjacent to the tumor were observed.
One reason could be due to the fact that the PDA tumor/normal paired tissue samples
were obtained without using precise microdissection techniques. Therefore, the
normal-appearing samples could be contaminated with some tumor cells, or there may
have been a field effect in the normal-appearing tissue that was in close proximity to
the tumor, or there could have been micrometastasis to normal-appearing pancreatic
tissue.
As has been reported for those genes mentioned above, I determined that the
aberrant SEL1L splicing was also not caused by genomic DNA sequence alterations.
Aberrant expression of splicing factors may be the mechanism for the mis-splicing.
For instance, a core splice regulatory protein serine-arginine protein kinase 1 (SRPK1)
has shown up-regulation in pancreatic carcinomas [64]. Aberrant splicing factors may
cause binding to (or failure to bind to) splice enhancers located in the SEL1L gene
regions. This could explain why mis-spliced products were observed from the RTPCR using SELmRNA-1 primers but not SELmRNA-2 and -3 primers. The increase
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in aberrant splicing could also be caused by the changes of environmental factors,
such as elevated temperature and low pH that are frequent occurrences in tumor
tissues. A study of the tumor suppressor genes neurofibromatosis type 1 (NF-1),
neurofibromatosis type 2 (NF-2), and tuberous sclerosis 2 (TSC-2) conducted by Dr.
Kaufmann et al. suggested that the environmental alterations might change the
structures at the splice donor site and disturbed splicing [65].
Elela and colleagues [66, 67] used high-throughput RT-PCR and deep
sequencing to analyze the alternative splicing profiles of cancer-associated genes in
normal and tumor tissues for both ovarian and breast cancer. They found that certain
alternative splicing events significantly differed in the tumors relative to normal
tissues. However, the method that was used in this study could not provide a full view
of the alternative splicing events in the samples analyzed. Lukas et al. reported that the
presence of the aberrant splicing products of MDM2 in breast cancer specimens was
correlated with a shorter overall patient survival [58]. Their results suggest that
aberrant splicing in a tumor suppressor gene could be of clinical importance for cancer
patients.
To determine whether there are tumor-specific SEL1L transcripts in PDAC,
further tests with microdissected tissues and deep sequencing are necessary. Also
because of the limitation of the material and methods used in this study, I was unable
to determine whether mis-splicing was associated with the altered expression of
SEL1L in PDAC.
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Chapter 2

Loss of Heterozygosity in the SEL1L Gene
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2.1 Introduction
Loss of heterozygosity (LOH) is defined as the loss of one allele in a tumor at
a constitutionally heterozygous locus, and indicates loss of detection of one of the two
alleles at that locus. LOH can arise via several pathways, including deletion, gene
conversion, mitotic recombination, chromosome loss and amplification of one allele
[68]. When there is only one functional allele left on the other chromosome, the
product of a gene with LOH may be reduced, and it may not be expressed at levels
sufficient to permit the cell to function normally. LOH is a common occurrence in
cancer. In pancreatic adenocarcinomas, such allelic loss has been frequently observed
at chromosome 9p which contains the p16 gene, 17p which contains the p53 gene, and
18q which harbors SMAD4 [11, 69].
Microsatellites are good markers for LOH studies. Microsatellites are short
tandem repeats of DNA that are distributed throughout the genome. The number of
repeats often varies between two alleles, providing a high frequency of allelic
heterozygosity. Two polymorphic intragenic microsatellites containing cytosineadenine (CA) repeats in the SEL1L gene in the Italian population have previously been
described by Chiaramonte et al. CAR/CAL microsatellite is located in SEL1L intron2
and was reported with a heterozygosity frequency of 0.68; RepIN20 microsatellite is
located in intron20 with a heterozygosity frequency of 0.85 [70]. No other
microsatellites have been found in the SEL1L gene locus.
In this chapter, using these 2 microsatellite markers, I aimed to determine
whether LOH is observed at the SEL1L gene locus in PDAC, and whether LOH
correlates with the downregualtion of SEL1L.
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2.2 Materials and Methods

Materials
PDAC tumors and the matched normal-appearing adjacent pancreatic tissue
specimens were collected as described in Chapter 1. A total of 73 pairs of DNA
samples were tested in this study.

Real-time quantitative PCR (qPCR)
The expression levels of SEL1L mRNA were examined in the DNA Analysis
Facility at UTMDACC. The TaqMan Gene Expression Assay kit targeting SEL1L
(Applied Biosystems, Foster City, CA) were used for the assays. The assays were run
using the 7900HT Fast Real-Time PCR System (Applied Biosystems). RNA from the
matched normal-appearing adjacent tissue was used as a calibrator for the tumor.
SEL1L mRNA expression was normalized to that of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). All of the assays were run in duplicate. The relative
quantities (RQs) of mRNA or miRNA expression in the tumors were calculated as
described by Livak and Schmittgen [71]. A gene was considered to be downregulated
if RQ < 0.5 so that the gene expression in the tumor was less than half that in the
normal-appearing adjacent tissue. A gene was considered to be upregulated if RQ > 2,
which means that the gene expression in the tumor was more than twice that in the
normal-appearing adjacent tissue.
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Fluorescent fragment analysis
This technique involves using fluorescent primers during amplification to label
PCR products as described by Canzian et al [72]. Two kinds of fluorescent dyes HEX
and FAM were used for labeling. Two sets of primers were designed for each of the
microsatellite regions. The PCR amplifications were all carried out in a final volume
of 30 µL of a mixture containing 10 ng of DNA, 10 pmol of each primer,
deoxynucleotide triphosphates (dNTP) each at 0.25 mM, KCl (50 mM), MgCl2 (1.5
mM), Tris-HCl (10 mM, pH 8.3), and 1 unit of AmpliTaq Gold DNA Polymerase
(Applied Biosystems, Foster City, CA).
For the intron 2 microsatellite, the primers were as follows: CAR/CAL-1
(forward 5′-HEX-AAA ATT ACT GAC CTA CAA GAG GG-3′ and reverse 5′-TGG
GCT TGG TTA GTA CTT GG-3′). The reaction was started at 95°C for 5 minutes,
followed by 40 cycles (95°C for 45 seconds, 55°C for 45 seconds, and 72°C for 45
seconds) and then an extension of 72°C for 7 minutes. For another set of primers
CAR/CAL-2 (forward 5′-FAM-AAA AGG ACA GAA AAA GAC AGA TGG-3′ and
reverse 5′-GGG AGA GCT CAA TCA ACC AA-3′), the same PCR protocol was
applied except that the annealing temperature was 58.5°C. For the intron 20 region,
the primers were: REPIN20-1 (forward 5′-HEX-CGT ATT GGA TTA CTG GTG
GAA AG-3′ and reverse 5′-GGC AAG GAA CTG GGA AAG TTA C-3′) with an
annealing temperature of 58.5°C, and REPIN20-2 (forward 5′-FAM-GCC CCA GTG
TTG TTT TGT TT-3′ and reverse 5′-AGG CAA GGA ACT GGG AAA GT-3′) with
an annealing temperature of 60°C.
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Using a 3730 DNA Analyzer (Applied Biosystems), the PCR products were
separated by capillary electrophoresis and analyzed in the DNA Analysis Facility at
UTMDACC. Fluorescently labeled fragments were detected by the machine and the
lengths of the fragments and fluorescent signal strengths were determined by analysis
software. In the case of heterozygotes, the fluorescent signal strength of the PCR
products from constituent alleles between tumor and its paired normal tissue was
compared. A ratio was calculated as follows: (tumor peak 1 / tumor peak 2) / (normal
peak 1 / normal peak 2). The average ratio from both primer sets was counted as the
final result. A ratio greater than 1.500 (3/2) or less than 0.667 (2/3) was considered as
positive evidence for the presence of LOH in the tumor. For example, in Figure 6B,
the ratio was calculated as: (16273 / 5684) / (12073 / 9278), which is 2.127 and
indicates that LOH displays in this tumor sample.
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2.3 Results

LOH is detectable in a small proportion of the PDAC tumors
Figure 6 shows representative results of the fluorescent fragment analysis. In
Figure 6A, a normal-appearing adjacent tissue specimen shows a single-peak of
fluorescence signal at the RepIN20 microsatellite locus indicating homozygosity for
this marker. Normal samples that are homozygous at a particular microsatellite marker
cannot provide information of allelic change in the tumor; therefore they were not
scored for LOH. In Figure 6B, both the PDAC tumor and its normal-appearing
adjacent tissue shows a double-peak at the CAR/CAL microsatellite locus indicating
heterozygosity for this marker, and a partial loss of the second peak is observed in the
tumor sample.
As shown in Table 1, 8 out of 55 (14.5%) informative samples displayed LOH
at the CAR/CAL locus, and 6 out of 56 (10.7%) informative samples displayed LOH
at RepIN20. Of these, 4 samples displayed LOH at both loci. Totally LOH was seen in
10 samples. Of the 73 PDAC tumor samples in this study, 8 were homozygous at both
microsatellite loci, so that the LOH information was obtained from only 65 samples.
In total, 10 out of 65 (15.4%) of these PDAC tumor samples displayed LOH at one or
both loci.

SEL1L LOH is not associated with its downregulation at the RNA level
SEL1L qPCR results were available for only 49 out of the 65 informative
sample pairs due to the quality of the corresponding RNA samples. In the group of
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samples displaying SEL1L LOH (total n = 8), 5 samples presented with SEL1L
downregulation and 3 samples presented with normal SEL1L expression. In the group
of samples without LOH (total n = 41), 24 samples presented with SEL1L
downregulation and 17 with normal SEL1L expression. Using Fisher’s exact test to
evaluate the association between the presence of LOH in SEL1L gene region and the
expression of SEL1L mRNA, LOH is not significantly associated with SEL1L
downregulation (P = 0.300).
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Figure 6. Chromatograms of fluorescent fragment analysis. Each peak has two
labels: number in the upper box gives the length of the PCR fragment, and number in
the lower box indicates the signal strength. A. Result for homozygous specimen. B.
Heterozygosity in a tumor and in its paired normal-appearing adjacent tissue. Allelic
loss can be seen at the second peak in the tumor.
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2.4 Discussion
In this study, LOH was detected at two SEL1L intragenic microsatellite loci
(CAL/CAR and RepIN20) in 15.4% of the PDAC tumors (Table 1). Fluorescent
fragment analysis results showed an imbalanced relative intensity rather than total loss
of one allele. Because of the heterogeneity of cancer cells, it is possible that LOH is
not displayed in every single tumor cell but only in a sub-population of the cells. Also,
because the samples that were studied were not from tissue micro-dissection, the
tumor samples may contain some non-tumor tissue. Therefore, this may explain a
partial allelic loss in the cases displaying LOH.
The results indicate that genome instability exists in the SEL1L gene region in
a small portion of PDACs. Although it was not possible to determine the exact
boundaries of the region of allelic loss by performing LOH analysis, the presence of
LOH indicates that there is a genomic abnormality in the SEL1L gene region that
could possibly lead to the production of aberrant SEL1L proteins.
In this study, there was no evidence showing that LOH correlated with SEL1L
mRNA downregulation. This may be because one functional allele is sufficient to
maintain the normal expression of SEL1L. However, even if the expression level of
SEL1L mRNA is normal, if aberrant SEL1L proteins are generated, they may
competitively interrupt the binding of normal SEL1L protein to the unfolded proteins
for degradation.
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Chapter 3

SEL1L CpG Island Methylation
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3.1 Introduction
Gene promoter regions usually contain a cluster of cytosine-guanine
dinucleotides (CpG) known as CpG islands. Hypermethylation of the cytosine residues
in CpG sites may induce chromatin condensation and inhibit the binding of
transcription factors, resulting in repression of gene expression [73, 74]. Aberrant CpG
island methylation is a common epigenetic mechanism for transcriptional silencing of
tumor suppressor genes [75]. Some of the most frequently reported genes that are
silenced by DNA methylation include CDKN2A/p16-INK4 in lung cancer, colorectal
cancer, and gastric carcinoma [76-78]; Ras association domain family 1 (RASSF1) in
gliomas, lung cancer, and ovarian cancer [79-81]; and O6-methylguanine-DNA
methyltransferase (MGMT) in lung cancer and colorectal cancer [82, 83]. Aberrant
promoter methylation of p16-INK4 has been seen in 52% of PDAC cases [84]. Some
other genes that have been found to display hypermethylation in PDAC include the
multiple endocrine neoplasia I (MEN1) and serpin peptidase inhibitor B5
(SERPINB5) [85, 86].
In this chapter, the goal was to determine whether hypermethylation
contributes to SEL1L downregulation.
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3.2 Materials and Methods

Materials
DNA was extracted from 41 PDAC tumors and 6 PDAC cell lines. Of the cell
lines, MDAPanc3, MDAPanc28 and MDAPanc48A were established in our
laboratory, and Panc-1, Capan-2 and AsPC-1 cell lines were purchased from the
American Type Culture Collection (ATCC, Manassas, VA).

Bisulfite DNA sequencing
The bisulfite (BS) modification method is commonly used to determine the
pattern of DNA methylation. Sodium bisulfite is a chemical compound with the
chemical formula NaHSO3. It can deaminate cytosine into uracil, but does not affect
the methylated form of cytosine with a methyl group attached to carbon 5 [87].
Therefore, the methylated and unmethylated cytosines can be distinguished from one
another by using this method (Figure 7).
DNA samples were treated with BS using the EZ DNA Methylation Gold Kit
(Zymo Research, Orange, CA). The treatment started from 1ug of genomic DNA in a
20µL reaction. The procedure was carried out according to the manufacturer’s
instructions. The modified SEL1L promoter region was amplified by PCR, and the
PCR products were subsequently analyzed by either pyrosequencing or Sanger
sequencing. Universal methylated DNA and universal unmethylated DNA (Zymo
Research) were used as controls to assess the efficiency of BS-mediated conversion
for both sequencing methods.

36

For pyrosequencing, nested PCR reactions were performed. The first set of
PCR primers was SEL1Lmeth1 (forward 5′-GTT GAA TTT AGG GGT TAT TAA
TTA GTT GGG-3′ and reverse 5′-TTC TAA TCC AAT CAC CAT AAT CTC CC-3′);
and the nested primers were SEL1Lmeth2 (forward 5′-ATT TAG GGG TTA TTA
ATT AGT TGG GGT T-3′ and reverse 5′-biotin-AAA ATC ATT CAT TAA CCA
ATC ATT ATA C-3′). The sequencing primer was SEL1LmethS (5′-TTA GTT GGG
GTT ATG-3′). Four CpG sites were included in the analyzed sequence, and the
methylation status of these sites was evaluated for 24 of the PDAC tumors and 6 cell
lines using the PSQ HS96A system (Biotage, Foxboro, MA) and the allele
quantification module.
For Sanger sequencing, nested PCR was performed of the entire CpG island of
SEL1L. The first set of primers was SEL1Lmeth3 (forward 5′-GAT GAG TTT TTT
TTT TTT AGT TTT GGA TTT A-3′ and reverse 5′-TCC TAT ATC AAA ATT CAT
TCC TTT AAA AT-3′), and the set of nested primers was SEL1Lmeth4 (forward 5′ATT TAG GGG TTA TTA ATT AGT TGG GG-3′ and reverse 5′-CAC TCC ACC
TTC CTA AAT AAC C-3′). The PCR products were purified with a QIAquick PCR
Purification Kit (Qiagen) and then sequenced in the DNA Analysis Facility at
UTMDACC using ABI PRISM 3730 DNA sequencers (Applied Biosystems, Foster
City, CA). SEL1Lmeth4 reverse primer was used as sequencing primer. With this
sequencing method, the methylation status of the 6 PDA cell line and 17 PDAC tumor
DNAs were evaluated.
The PCR amplification was carried out in a final volume of 30 µL of a mixture
containing 10 pmol of each primer, deoxynucleotide triphosphates (dNTP) each at
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0.25 mM, KCl (50 mM), MgCl2 (1.5 mM), Tris-HCl (10 mM, pH 8.3), and 1 unit of
AmpliTaq Gold DNA Polymerase (Applied Biosystems). For the reactions using the
first set of primers (SEL1Lmeth1 or SEL1Lmeth3), 2 ul of BS-treated DNA was
added as template. For the reactions using the nested primers (SEL1Lmeth2 or
SEL1Lmeth4), 1 ul of the PCR product from the first round was used as template. The
reactions were started at 95°C for 5 minutes, followed by 40 cycles (95°C for 45
seconds, proper annealing temperature for 45 seconds, and 72°C for 45 seconds) and
then an extension of 72°C for 7 minutes.
SEL1L CpG island sequences and locations of the primers are shown in Figure
8.
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A.

B.

Figure 7. Bisulfite sequencing for methylation detection.
A. Bisulfite treatment flowchart (picture is modified from Zymo Research company
website); B. Sequence after BS treatment at CpG site for methylated and unmethylated
DNA.
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ctgggaattgtagtctcggatgagcctctttctcccagtcttggactcacgcgctgattc
TTGGGAATTGTAGTTTCGGATGAGTTTTTTTTTTTTAGTTTTGGATTTACGCGTTGATTT
SEL1Lmeth3F
cggttgaacccaggggctaccaattagctggggccatgtccgtgagtcgtggtccaaccg
CGGTTGAATTTAGGGGTTATTAATTAGTTGGGGTTATGTTCGTGAGTCGTGGTTTAATCG
SEL1Lmeth1F SEL1Lmeth4F SEL1Lmeth2F
agaaagctggtgtgggagcttcgtacaatgattggccaatgaatgacccccggggcggag
AGAAAGTTGGTGTGGGAGTTTCGTATAATGATTGGTTAATGAATGATTTTCGGGGCGGAG
SEL1Lmeth2R
caatgggggtgggcggggagaccatggtgattggaccagaagcccgcgacggcgggcggg
TAATGGGGGTGGGCGGGGAGATTATGGTGATTGGATTAGAAGTTCGCGACGGCGGGCGGG
SEL1Lmeth1R
gattggctgcgcgctgggtcagggaagcctgggaaggggcggaggaaggagactagagca
GATTGGTTGCGCGTTGGGTTAGGGAAGTTTGGGAAGGGGCGGAGGAAGGAGATTAGAGTA

ggaagagcagcggcgaggcggcggtggtggctgagtccgtggtggcagaggcgaaggcga
GGAAGAGTAGCGGCGAGGCGGCGGTGGTGGTTGAGTTCGTGGTGGTAGAGGCGAAGGCGA

cagctctaggggttggcaccggccccgagaggaggatgcgggtccggatagggctgacgc
TAGTTTTAGGGGTTGGTATCGGTTTCGAGAGGAGGATGCGGGTTCGGATAGGGTTGACGT

tgctgctgtgtgcggtgctgctgagcttggcctcggcgtcctcgggtcagtatccgcccc
TGTTGTTGTGTGCGGTGTTGTTGAGTTTGGTTTCGGCGTTTTCGGGTTAGTATTCGTTTT
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ctcgggctgaaggcccagagcctccgccccccagcctctacagccggcggggccgtgggg
TTCGGGTTGAAGGTTTAGAGTTTTCGTTTTTTAGTTTTTATAGTCGGCGGGGTCGTGGGG

actccaggctcgggaccccgttctccctgggcacatctcgcactgggctgtcactcgctc
ATTTTAGGTTCGGGATTTCGTTTTTTTTGGGTATATTTCGTATTGGGTTGTTATTCGTTT

tttggctttgcttggcctgcgccaaaggggctatttaggaaggtggagtggggtggaaaa
TTTGGTTTTGTTTGGTTTGCGTTAAAGGGGTTATTTAGGAAGGTGGAGTGGGGTGGAAAA
SEL1Lmeth4R
agaaggggcggtcaccctgcccacacctctctcccacgtaacaaactttgcgcgactctt
AGAAGGGGCGGTTATTTTGTTTATATTTTTTTTTTACGTAATAAATTTTGCGCGATTTTT

ctcacgaacgcggaattgactccaaaggaatgaatcctgatacaggagcccgagtggagc
TTTACGAACGCGGAATTGATTTTAAAGGAATGAATTTTGATATAGGAGTTCGAGTGGAGT
SEL1Lmeth3R

Figure 8. SEL1L CpG island sequences and locations of BS PCR primers.
Yellow highlight: SEL1L CpG island; Lower case: original sequence before BS
treatment; Upper case: converted sequence after BS treatment; Underline: CpG site; Red
rectangle: primers for BS pyrosequencing PCR; Blue rectangle: primers for BS Sanger
sequencing PCR; Italic: SEL1LmethS.

41

3.3 Results

Methylation is not detected in the SEL1L promoter CpG island
BS sequencing results of the universal unmethylated control showed complete
conversion of all the cytosine residues, and the universal methylated control showed
conversion of all the cytosine residues except for those at the CpG sites. These results
indicated that the BS treatment worked successfully and could detect the methylation
status of SEL1L CpG island reliably.
The BS pyrosequencing method examined 3 CpG sites with high fidelity in the
SEL1L promoter region. All of the samples analyzed by this method presented with
100% of thymine (T) and 0% of cytosine (C) at the covered CpG sites, which
indicated a lack of methylation at these sites. Sanger sequencing of BS-treated DNA
also did not display evidence for methylation at the examined CpG sites in any of the
samples. Representative results of both sequencing methods are shown in Figure 9.
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A.

B.

Figure 9. Bisulfite sequencing results.
A. Pyrosequencing chromatogram indicating that at all three CpG sites the cytosines
were 100% unmethylated; D. Sanger sequencing chromatogram showing a sequence
from reverse direction without methylation.
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3.4 Discussion
The advantage of the pyrosequencing method is that it is quantitative, so it was
possible to determine if the levels of hypermethylation detected in the tumor tissues
were greater than in the normal adjacent tissues by comparing the cytosine/thymine
ratio. The disadvantage of this method was that only a few of the CpG sites in one run
could be detected which might not represent the whole CpG island.
The advantage of the Sanger sequencing method was that the methylation
status of the whole CpG island could be evaluated. The disadvantage was that after
bisulfite treatment, the converted DNA might contain poly T or poly A. When the poly
T/A sequences are too long, it would be difficult to sequence by this method. Sanger
sequencing without cloning only gives information about the average product. To get
statistically meaningful data commonly cloning and sequencing individual molecules
are needed.
Both of the sequencing methods were used for this study as they are
complementary to each other and the results using one method can be confirmed by
the other. The results suggest that hypermethylation is not a mechanism of SEL1L
downregulation. However, in some rare cases, alternate promoters containing CpG
islands may exist in or around some genes which can also regulate gene expression.
This possibility can be further studied for the SEL1L gene.

44

Chapter 4

SEL1L and MicroRNA
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4.1 Introduction
MiRNAs are endogenous non-coding RNAs ~ 18–24 nucleotides long.
Generally, miRNAs bind to the 3′ untranslated region (UTR) of their target genes
through imperfect complementation and repress gene expression either by increasing
mRNA degradation or by inhibiting translation [88]. Whether the binding of miRNA
drives mRNA degradation or translational inhibition of the target gene depends on the
structure of the miRNA–mRNA duplex. Many studies have reported that miRNA may
repress target gene translation even when it does not affect the mRNA level [89].
Emerging evidence shows that deregulated miRNAs may play an oncogenic or
tumor-suppressive role in different kinds of cancers by repressing the expression of
oncogenes or tumor suppressor genes [90, 91]. In PDAC, it has been reported that
microRNA-155 inhibits the expression of tumor suppressor gene tumor protein 53induced nuclear protein 1 (TP53INP1), and microRNA-21 regulates the expression of
the tumor suppressor programmed cell death 4 (PDCD4) [92, 93]. Because miRNAs
can be shed into the serum and be isolated and studied, they may serve as biomarkers
for early detection and diagnosis of cancers, and for evaluating patients’ prognoses
[94]. In addition, the functional involvement of these miRNAs in tumorigenesis makes
them potential therapeutic targets for the treatment of PDAC [95, 96].
The 3′ UTR of the SEL1L gene is larger than 4000 bp and thus provides great
potential to bind miRNAs. Using miRNA microarrays, three studies have investigated
the genome-wide alterations in miRNA expression found in PDAC [97-99]. There are
18 miRNAs that displayed upregulation in PDAC in at least two of these studies. In
this study, I sought to determine whether these aberrantly upregulated miRNAs are

46

responsible for SEL1L downregulation in PDAC using both statistical and functional
analysis.
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4.2 Materials and Methods

Materials
RNA samples from a total of 42 tumor/normal pairs were examined using
qPCR. Protein samples from 40 out of the 42 pairs have been used for Western
blotting. MDAPanc3, MDAPanc28, MDAPanc48A and MDAPanc48B cell lines were
established in our laboratory, all other cell lines used in this study were purchased
from ATCC.

Extraction of DNA, RNA, and Protein
Total RNA including miRNA extraction and DNA extraction have been
previously described in the Methods section in Chapter 1. Protein was isolated from
the phenol–ethanol supernatant obtained after precipitation of the RNA and DNA.
Protein concentrations were determined with the bicinchoninic acid (BCA) protein
assay reagents (Pierce, Rockford, IL).

MiRNAs predicted to target SEL1L
The microRNA.org resource (miRanda) was searched to identify which of the
18 aberrantly upregulated miRNAs were predicted to target SEL1L. MiRanda is a
comprehensive resource for miRNA target predictions that computes the optimal
sequence complementarity between a mature miRNA and an mRNA using a weighted
dynamic programming algorithm [100]. From the search, 7 miRNAs were identified
that potentially target SEL1L: hsa-mir-143, hsa-mir-155, hsa-mir-181a, hsa-mir-181c,
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hsa-mir-205, hsa-mir-210, and hsa-mir-223. The predicted binding sites and the
chromosomal locations of these miRNAs are shown in Table 2.
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qPCR
Assessment of SEL1L mRNA expression has been described in the Methods
section in Chapter 2. The expression levels of the 7 mature miRNAs were examined
in the DNA Analysis Facility at UTMDACC. The TaqMan MicroRNA Assay kits
individually targeting the 7 miRNAs (Applied Biosystems) were used for the assays.
RNA from the matched normal-appearing adjacent tissue was used as a calibrator for
the tumor. Expression of the miRNAs was normalized to that of U6B small nuclear
RNA (RNU6B). All of the assays were run in duplicate and an average RQ was
calculated as final result. Again, a gene was considered to be upregulated if RQ > 2,
and was considered to be downregulated if RQ < 0.5.

Western blotting
Thirty micrograms of each of the protein samples were resolved on 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Then
proteins were transferred to 0.45 µM nitrocellulose membrane (Bio-Rad Laboratories,
Hercules, CA). A goat polyclonal antibody to SEL1L (Santa Cruz Biotechnology,
Santa Cruz, CA) was used at 0.8 µg/mL in tris-phosphate buffered saline (TPBS) with
5% Blotto (GE Healthcare, Piscataway, NJ). Bovine anti-goat immunoglobulin Ghorseradish peroxidase (IgG-HRP) secondary antibody (Santa Cruz Biotechnology)
was used at a dilution of 1:5000. TPBS with 0.2% Tween20 (Sigma-Aldrich, St.
Louis, MO) was used as washing buffer to reduce the high background of non-specific
blotting when using a goat antibody. The membrane was washed 3 times for 15
minutes following antibody incubation. The GAPDH antibody (Abcam, Cambridge,
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MA) was used as a loading control at a concentration of 0.4 µg/mL. Goat anti-rabbit
IgG-HRP (Santa Cruz Biotechnology) was used as a secondary antibody to GAPDH at
a dilution of 1:5000. The membrane was washed in TPBS with 0.05% Tween20 3
times for 10 minutes following the antibody incubation.
Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare)
were used to detect the signals. The intensity of the bands on Western blots was
measured with Quantity One version 4.6.1 analysis software (Bio-Rad Laboratories).
Desired bands from two exposure times (20 seconds and 1 minute) were quantified,
and their average intensities were calculated. The RQ of SEL1L protein expression in
the tumor was normalized to that of GAPDH and compared with that of the matched
normal-appearing adjacent tissue.

Statistical analysis
The Fisher’s exact test was used to evaluate the association between the
expression levels of SEL1L mRNA and the miRNAs. The Kruskal–Wallis test was
used to evaluate expression differences between the groups with 0, 1, 2, or 3
upregulated miRNAs. Pearson’s correlation coefficient was used to measure the
correlation between SEL1L mRNA expression and SEL1L protein expression in
PDAC tumors. All tests of statistical significance were 2-sided. P < 0.05 was
considered statistically significant. All statistical analyses were performed using Stata
version 10.1 software (Stata, College Station, TX).

Cell culture
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The PDAC cells, including Panc1, BxPC3, MiaPaCa2, ASPC1, Capan1,
Capan2, PL3, PL18, MDAPanc3, MDAPanc28, MDAPanc48A and MDAPanc48B, as
well as Human Embryonic Kidney (HEK) 293T cells were maintained at 37°C and
5% CO2 in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12)
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (FBS)
(Gemini Bio-Products, West Sacramento, CA) and 1% penicillin/streptomycin
(Mediatech). The hTERT-HPNE cells were cultured in 75% DMEM without glucose
(Mediatech), 25% Medium M3 Base (Incell Corporation, San Antonio, TX)
supplemented with 10 ng/ml human recombinant EGF (Sigma-Aldrich), 5.5 mM Dglucose (Mediatech), 5% FBS and 0.75% puromycin (Mediatech).

Luciferase assay
The pMIR-REPORT miRNA Expression Reporter Vector System (Applied
Biosystems) was used to determine whether the miRNAs bind to the predicted binding
sites and regulate reporter expression. The pMIR-REPORT Luciferase Reporter
Vector may produce high-level expression of firefly luciferase under the control of a
mammalian promoter/terminator system. The miRNA target cloning region is located
downstream, i.e. 3’ UTR, of the luciferase sequence. The predicted SEL1L–miRNA
binding sites and more than 100 bp of flanking sequence at both the 5’ and 3’ ends
were inserted into the cloning region. Because the putative binding sites for hsa-mir155 and hsa-mir-223 are very close to each other, a construct containing the putative
binding sites for both of the miRNAs was established (Figure 10). The 100 bp
flanking sequences help to ensure that the secondary structure of the binding sites will
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not be interrupted and thus better represent the in vivo condition. A second vector,
pMIR-REPORT Beta-galactosidase (ß-gal) Reporter Vector,

was

used

for

normalization of transfection efficiency. A relative expression of the firefly luciferase
was calculated by comparing that to the expression of ß-gal signal. For example, the
average reading of the firefly luciferase signal in a sample was 6288437 and the
average reading of the ß-gal signal in this sample was 47494, so the relative
expression of the firefly luciferase was 6288437 / 47494 = 132.40.
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A.
CTGAGAAACTCTTACCAGTCCACATGCAATTAGACATATTCAGCATATTTGTTATTTTAAAAGGGAGGG
TTGGGAGGTTTCTTATTGGTGATTGTCACACGGTATACCATACTCCTCTCCTTCAAAGAATGAAAGGCC
TTGTTAAGGAGTTTTTTGTGAGCTTTACTTCTTTGGAATGGAATATACTTATGCAAAACCTTGTGAACT
GACTCCTTGCACTAACGCGAGTTTGCCCCACCTACTCTGTAATTTGCTTGTTTGTTTTGAATATACAGA
GCCTTGATCCAGAAGCCAGAGGATGGACTAAGTGGGAGAAATTAGAAAACAAAACGAACTCTGGTTGGG
GTACTACGATCACAGACACAGACATACTTTTCCTAAAGTTGAAGCATTTGTTCCCAGGATTTATTTTAC
TTTGCATTTCTTTTTGCACAAAGAACACATCACCTTCCTGAATTCTTTAAATATGAAATATCATTGCCA
GGGTATGGCTTACAGTGACTACTATTATAATACTAAAACTCAGAGAATCAAAGATGGATTAAACTCAGT
GGTTGATGAAAGCCAAAACCTGTTTGTACTGTTCTATACTATTCAGGTATCTTTTTATTTCTGATAGTT
TTATATTATAATAGAAAGCCAGCCACTGCTTAGCTATCATAGTCACCATTTTCTCACTGTTAACATTAG
GAAAATCAAGGCTACTATGCTTCAGGATTGTCTGGTTAAATAGTATGGGAAAAAAACTGAAGAGTTTCA
CATAATTACACACGTGAAATAATTAAAGCTT

B.

Figure 10. pMIR-REPORT Luciferase Reporter construct containing predicted
binding sites of SEL1L to hsa-mir-155 and hsa-mir-223. A. Sequence that was
inserted into the vector. Yellow highlight: hsa-mir-223 binding site; Red highlight:
hsa-mir-155 binding site. B. Schematic diagram of the construct.
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MDAPanc3 cells, PL18 cells or BxPC2 cells were plated in 6-well plates and
reached a cell confluency of 50%-60% at the time of transfection. In each well, a
mixture of 1.5 ug of Luciferase Reporter plasmid DNA (with or without the binding
sites) and 0.15 ug of ß-gal Reporter plasmid DNA was transfected into the cells with 5
ul of Lipofectamine LTX (Invitrogen) and 1.65 ul of PLUS reagent (Invitrogen). Cells
were washed with PBS twice and collected after 24 hours and 48 hours. Firefly
luciferase activity and ß-gal activity were determined by using the Dual-Light
Luciferase and ß-Galactosidase Reporter Gene Assay System (Applied Biosystems)
according to the manufacturer’s instructions. A 20/20n Single Tube Luminometer
(Turner Biosystems, Sunnyvale, CA) was used for the measurements. All of the
transfections were performed in triplicate and the average activities were calculated.
Then the firefly luciferase activities were normalized to ß-gal activity.
293T cells were plated in 24-well plates and transfected at a cell confluency of
80-90%. The cells were transfected with 200 ng of Luciferase Reporter plasmid DNA
(with or without the binding sites), 5ng of ß-gal Reporter plasmid DNA, and 5 pmol of
miRNA precursor or negative control (final concentration 25 nM) using 2 ul of
Lipofectamine2000 (Invitrogen). The miRNA precursors and negative control (miRcontrol) were purchased from Ambion/Applied Biosystems. The miRNA precursors
are synthetic, chemically modified double-stranded RNA molecules that mimic
endogenous mature miRNAs. The negative control is similar to the miRNA precursor
with a random sequence that has been validated not to produce identifiable effects on
known miRNA function. Cells were harvested after 48 hours of the co-transfection.
Firefly luciferase activity and ß-gal activity were assessed as described in the last
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paragraph.

MiRNA inhibition and overexpression
Chemically modified antisense oligoribonucleotides, termed “antagomirs”,
were used in this study to inhibit hsa-mir-155 and hsa-mir-223. Antagomirs have been
reported to specifically, efficiently reduce the expression of corresponding miRNAs
[101]. The antagomir against hsa-mir-155 is: 5’-mA*mC*mCmCmCmUmAmUmCmAmCmGmAmUmUmAmG-mCmAmU*mU*mA*mA*/Chol-3’.

The

antagomir

against hsa-mir-223 is: 5’-mU*mG*mGmGmGmUmAmUmUmUmGmAmCmAmA
mAmCmUmG*mA*mC*mA*/Chol-3’. The negative control for the antagomirs is: 5’mA*mA*mGmUmGmGmAmUmAmUmUmGmUmUmGmCmCmA*mU*mC*mA*/
Chol-3’. The lower case “m” represents 2’-O-methyl-modification; the asterisk
(*) represents a phosphor-rothioate linkage; and “Chol” represents cholesterol linked
through a hydroxyprolinol linkage. The negative control is a random sequence that has
been validated by Ambion not to inhibit any known miRNA function. These
antagomirs were synthesized and then purified by high-performance liquid
chromatography (Integrated DNA Technologies, Coralville, IA).
BxPC3, PL18 or Capan2 cells were plated in 6-well plates and reached a cell
confluency of 50%-60% at the time of transfection. In each well, 200 pmol of the
antagomir or negative control (final concentration 200 nM) was transfected into the
cells with 2 ul of Oligofectamine (Invitrogen). For PL18 cells, after 24 hours of
transfection, a double knockdown was performed by transfecting the same amount of
hsa-mir-155 antagomir into the cells again.
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Ambion miRNA precursors and negative control were used for the
overexpression study of the miRNAs of interest. MDAPanc3 or Miapaca2 cells were
plated on 6-well plates and reached a cell confluency of 50%-60% at the time of
transfection. In each well, 30 pmol of miRNA precursor or negative control (final
concentration 30 nM) was transfected into the cells using 2 ul of Oligofectamine
(Invitrogen).
The cells mentioned above were washed with PBS twice and collected after 24
hours, 48 hours and 72 hours. Then total RNA and protein were extracted for qPCR
and Western blotting as described previously. Proteins also were extracted by lysing
the cells in Radio-Immunoprecipitation Assay (RIPA) buffer (Sigma-Aldrich).

Reverse phase protein assay (RPPA)
The cell lysates were denatured with 1% SDS (with beta-mercaptoethanol) and
diluted in five 2-fold serial dilutions in lysis buffer containing 1% SDS. Serial diluted
lysates were arrayed on nitrocellulose-coated slides (Grace Bio-lab, Bend, OR) using
an Aushon 2470 Arrayer (Aushon BioSystems, Billerica, MA). Each slide was probed
with validated primary antibodies plus biotin-conjugated secondary antibodies. A total
of 172 antibodies including 23 replicated antibodies were included in the data set
(SEL1L antibody was not available for this experiment). All the proteins assessed are
related to cancer pathogenesis. Each array included spots corresponding to positive
and negative controls prepared from mixed cell lysates or dilution buffer, respectively.
The signal obtained was amplified using a Dako Cytomation–catalyzed system (Dako,
Carpinteria, CA) and visualized by diaminobenzidine (DAB) colorimetric reaction.
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The slides were scanned, analyzed, and quantified using a customized-software
Microvigene (VigeneTech Inc., Carlisle, MA) to generate spot intensity. Protein levels
for each sample were determined by interpolation of each dilution curve into a logistic
model, Supercurve Fitting, developed by the Department of Bioinformatics and
Computational Biology at UTMDACC [102]. This model fits a single curve using all
the dilution series on a slide with the signal intensity as the response variable and the
dilution steps as independent variables. The protein concentrations of each set of slides
were then normalized by median polish, which was corrected across samples by the
linear expression values using the median expression levels of all antibody
experiments to calculate a loading correction factor for each sample. A relative protein
expression level was calculated by comparing the normalized linear value in the
sample transfected with miRNA precursor to that in the sample transfected with
negative control at the same time point. A protein was considered to be upregulated if
RQ > 1.500, and to be downregulated if RQ < 0.667.

Ingenuity pathways analysis (IPA)
The “Core Analysis” function in IPA (Ingenuity System Inc, Redwood City,
CA) was used to interpret the RPPA data for pathways and networks involved [103].
Molecules from the data set that displayed expression variation and were contained in
the Ingenuity Knowledge Base were analyzed. The significance of the association
between the data set and the canonical pathway was measured by Fisher’s exact test to
calculate a P‐value. These molecules were also overlaid onto a global molecular
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network developed from information in the Ingenuity Knowledge Base, and networks
were then algorithmically generated based on their connectivity.
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4.3 Results

Expression levels of hsa-mir-143, hsa-mir-155, and hsa-mir-223 are inversely
correlated with SEL1L mRNA expression in PDAC tumors
Results from quantitative RT-PCR indicated that SEL1L mRNA was
downregulated in 55% of the PDAC tumors, whereas the 7 miRNAs were upregulated
in the following percentages of the PDAC tumors: hsa-mir-155, 52%; hsa-mir-205,
45%; hsa-mir-210, 45%; hsa-mir-181c, 40%; hsa-mir-143, 38%; hsa-mir-181a, 35%;
and hsa-mir-223, 33% (Figure 11).
The RQs of the expression of SEL1L mRNA and the 7 miRNAs were initially
assessed in 20 pairs of PDAC tumors and normal-appearing adjacent tissues by qPCR.
The preliminary data showed that only levels of hsa-mir-143, hsa-mir-155, and hsamir-223 correlated significantly with SEL1L mRNA expression. Subsequent analyses
of an additional 22 pairs of samples for these 3 miRNAs corroborated these findings,
and the combined data from a total of 42 samples pairs are presented in Table 3.
The downregulation of SEL1L mRNA was found to be significantly associated
with the upregulation of hsa-mir-143, hsa-mir-155, and hsa-mir-223 as evaluated
using Fisher’s exact test (P < 0.0001, P < 0.0001, and P = 0.002, respectively). As
shown in Table 3, of the samples in which these miRNAs were upregulated, 14 (88%)
out of 16, 18 (82%) out of 22, and 12 (86%) out of 14, respectively, showed SEL1L
mRNA downregulation. Furthermore, of the 23 tumor samples in which SEL1L
mRNA was downregulated, 20 (87%) displayed upregulation of at least 1 of these 3
miRNAs. The other 4 miRNAs (hsa-mir-181a, hsa-mir-181c, hsa-mir-205, and hsa-
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mir-210) did not show a significant correlation with SEL1L mRNA expression (P =
0.749, P = 0.763, P = 0.654, and P = 0.469, respectively).
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Figure 11. Percentage of the deregulation of SEL1L mRNA and 7 miRNAs in
PDAC tumors.
Blue columns indicate gene upregulation. Pink columns indicate gene downregulation.
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Inverse correlation between miRNA expression and SEL1L expression
As shown in Figure 12, the samples were divided into 4 groups on the basis of
the number (0, 1, 2, or 3) of upregulated miRNAs in each sample. Because only hsamir-143, hsa-mir-155, and hsa-mir-223 showed correlations with SEL1L mRNA
expression, this study was focused on the upregulation of these 3 miRNAs. The RQs
of SEL1L mRNA expression in the tumors were compared for the groups. It was
determined that as the number of overexpressed miRNAs increased, the median RQ of
SEL1L mRNA expression decreased. The RQs of SEL1L mRNA expression among
the four groups were significantly different (P = 0.004), and the trend of an increasing
number of upregulated miRNAs corresponding to decreasing expression of SEL1L
mRNA was also significant (Ptrend = 0.001).
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Figure 12. RQ of SEL1L mRNA expression in PDAC tumors plotted against the
number of upregulated miRNAs.
Each horizontal line of pluses (+) and the number next to it represent the median fold
change in SEL1L mRNA expression for that number of upregulated miRNAs.
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The expression levels of hsa-mir-143, hsa-mir-155, and hsa-mir-223 are
significantly associated with each other
The pairwise association was also evaluated between hsa-mir-143, hsa-mir155, and hsa-mir-223 using Fisher’s exact test (Table 4). Of the 42 tumor samples, 26
(62%) showed the same trend of expression between hsa-mir-143 and hsa-mir-155, 25
(60%) between hsa-mir-143 and hsa-mir-223, and 24 (57%) between hsa-mir-155 and
hsa-mir-223. They were all significantly associated with each other (P = 0.015, P =
0.003, and P = 0.010, respectively).
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SEL1L protein expression correlates significantly with SEL1L mRNA expression
Because miRNAs may block target gene translation directly [88], SEL1L
protein expression levels were assessed to determine whether the protein levels
parallel the mRNA levels or whether the proportion of downregulation in PDAC
tumors is greater at the protein level than at the mRNA level. The results are shown in
Table 5. For both SEL1L mRNA and SEL1L protein, again the RQs of 2 and 0.5 were
used as the cutoff values for considering a gene to be up- and downregulated. In those
samples where the mRNA and the protein showed different trends of expression,
Western blotting was repeated and the average RQ was calculated as the final result.
Of the 40 PDAC tumor samples listed in Table 5, it was determined that unlike
SEL1L mRNA that was downregulated in 21 (53%) of the PDAC tumors, SEL1L
protein was downregulated in only 16 (38%). In these 16 tumors, SEL1L mRNA was
always downregulated. SEL1L mRNA and SEL1L protein displayed the same trends
of expression (both up, both down, or both normal) in 32 (80%) of the 40 cases. The
representative results of Western blotting are shown in Figure 13A. Pearson’s
correlation test showed that the RQ of SEL1L protein expression varied directly with
the RQ of SEL1L mRNA expression and was statistically significant (Figure 13B).
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A.

B.

Figure 13. SEL1L protein expression and comparison to its mRNA expression.
A. Representative results of Western blotting (cropped image). Sample numbers
follow table 5. T: PDAC tumor sample; N: normal adjacent tissue. B. Pearson's
correlation scatter plot of SEL1L mRNA and protein relative fold change in 40
PDACs. The plot shows linear regression with R2 = 0.605 (r = 0.778).
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Expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 in pancreatic cancer cell
lines were determined by qPCR
The hTERT-HPNE cell line was used as a “normal” control. This immortalized
cell line was derived from normal ducts of the human pancreas and is the closest thing
to normal human pancreas in terms of cell lines. The hTERT-HPNE cells have been
found to have the ability to differentiate into pancreatic ductal cells [104].
The expression levels of hsa-mir-143, hsa-mir-155 and hsa-mir-223 were
assessed in 12 pancreatic cancer cell lines and in the hTERT-HPNE cell line by qPCR.
The RQs of these 3 miRNAs in the PDAC cell lines were then compared to the
corresponding RQ in the hTERT-HPNE cell line. As shown in Figure 14, for hsa-mir143, all the PDAC cell lines displayed relatively low levels of expression; for hsa-mir155, the PDAC cell lines showed variable expression levels; for hsa-mir-223, only
BxPC3 displayed a high level of expression and all of the other11 PDAC cell lines
showed relatively low levels of expression.
The low expression level of hsa-mir-143 in the 12 PDAC cell lines indicates
that these cell lines cannot serve as an ideal model for hsa-mir-143 functional analysis.
Therefore, the functional analysis was focused on the other 2 miRNAs, hsa-mir-155
and hsa-mir-223.
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Figure 14. Expression of 3 miRNAs in PDAC cell lines.
Each column represents the relative expression level of the 3 miRNAs in the 12 PDAC
cell lines. The expression level in the hTERT-HPNE cell line was set as 1 fold. Names
of the miRNAs are labeled at the right, and names of the cell lines are labeled at the
bottom.
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pMIR-REPORT Luciferase Reporter construct vector showed decreased reporter
expression in PL18 cell line
The pMIR-REPORT Luciferase Reporter Construct with putative hsa-mir-155
and hsa-mir-223 binding sites was transfected into two PDAC cell lines, PL18 and
MDAPanc3, as described in the Methods. From the results in Figure 14, it was
determined that PL18 has a relatively high expression level of hsa-mir-155; and
MDAPanc3 has a very low expression level. Both of these 2 cell lines showed a low
level of hsa-mir-223 expression. In the PL18 cells transfected with the construct
vector, a significant decrease was found in firefly luciferase expression in comparison
to the cells transfected with empty vector. However, for the MDAPanc3 cell line, there
was no significant difference found in luciferase expression between the cells
transfected with the construct vector and with the empty vector. These results are
shown in Figure 15.
BxPC3 cells were also transfected with pMIR-REPORT Luciferase Reporter
Vectors using the same protocol. It was determined that BxPC3 has a high expression
level of both hsa-mir-155 and hsa-mir-223. However, there was no significant
difference observed between the results of transfection of the construct vector and of
the empty vector. It was noticed that the luciferase signal in BxPC3 cells was more
than 100 times lower than that in other cells indicating low transfection efficiency in
this cell line (data not shown). Therefore, the data obtained from experiments using
BxPC3 cells may not be reliable.
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Figure 15. Luciferase assay of pMIR-REPORT Luciferase Reporter Vector
transfection in 2 PDAC cell lines.
Empty: cells transfected with the vector without an insert. Construct: cells transfected
with the vector containing the putative binding sites. The asterisk (*) indicates a
significant difference between the results from empty vector transfection and the
construct transfection (t-test, P < 0.05). Error bars indicate standard deviation of the
relative luciferase expression (n = 3).
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pMIR-REPORT Luciferase Reporter construct vector did not show difference in
reporter expression in 293T cells co-transfected with the miRNA precursors
The 293T cell line is a derivative of HEK 293 cell lines containing the SV40
Large T-antigen. This cell line is easily transfected with plasmids containing the SV40
origin of replication. Gironella et al. used this cell line to co-transfect a reporter
construct vector and hsa-mir-155 precusor [92]. Therefore, this cell line was chosen
for the co-transfection experiment. However, there was no significant difference found
in luciferase expression between the cells transfected with the negative control and
with the miRNA precursors. Luciferase assay results from co-transfection of either the
empty vector or the construct vector are shown in Figure 16.
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Figure 16. Luciferase assay of pMIR-REPORT Luciferase Reporter Vector cotransfection with miRNA precursors in 293T cell line.
Empty: cells transfected with the vector without an insert. Construct: cells transfected
with the vector containing the putative binding sites. The cells were co-transfected
with either the negative control, or 1 or 2 miRNA precursors. Error bars indicate
standard deviation of the relative luciferase expression (n = 3).
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SEL1L expression did not change after transfection of antagomirs
Because the BxPC3 cell line has very high expression levels of both hsa-mir155 and hsa-mir-223, the antagomirs were transfected into this cell line to evaluate
their effect on the expression of either one or two of the miRNAs. Real-time qPCR
results indicated that 24 hours and 48 hours after transfection of the hsa-mir-155
antagomir, the expression of hsa-mir-155 was more than 2 fold downregulated.
However, in the cells transfected with the hsa-mir-223 antagomir, there were no
obvious changes in the expression of hsa-mir-223. Both qPCR and Western blotting
did not reveal substantial changes in the expression of SEL1L at the mRNA level or
protein level, including in the samples where hsa-mir-155 was downregulated. Results
are shown in Figure 17.
The Capan2 cell line showed a moderate expression level of both hsa-mir-155
and hsa-mir-223. The antigomirs were transfected into this cell lines using the exact
same protocol as for BxPC3. Similar results were obtained as seen for the BxPC3 cell
line and the expression of SEL1L did not significantly change after the transfection of
the antagomir(s). The results are shown in Figure 18.
The hsa-mir 155 antagomir was also been transfected into PL18 cells. This
time, a double knockdown was performed as described in the Methods section. qPCR
results indicated that hsa-mir-155 was further downregulated 48 hours after the second
transfection (RQ = 0.18). However, there were still no substantial changes observed in
the expression of SEL1L at either the mRNA level or protein level. The results are
shown in Figure 19.
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Figure 17. Expression of SEL1L after transfection of antagomirs against hsa-mir155 and hsa-mir-223 in BxPC3 cells.
A. Relative quantities of hsa-mir-155, hsa-mir-223 and SEL1L mRNA determined by
qPCR. Anta, samples transfected with antagomir(s); NC, samples transfected with
negative control to antigomir; hr, hours after transfection. Sample numbers are noted
at the left of each name. Red numbers indicate downregulation. B. SEL1L protein
expression determined by Western blotting. Sample numbers are the same as those in
panel A.
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Figure 18. Expression of SEL1L after transfection of antagomirs against hsa-mir155 and hsa-mir-223 in Capan2 cells.
A. Relative quantities of SEL1L mRNA determined by qPCR. Anta, samples
transfected with antagomir(s); NC, samples transfected with negative control to
antigomir; hr, hours after transfection. Sample numbers are noted at the left of each
name. B. SEL1L protein expression determined by Western blotting. Sample numbers
are the same as those in panel A.
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Figure 19. Expression of SEL1L after transfection of antagomir against hsa-mir155 in PL18 cells.
A. Relative quantities of SEL1L mRNA determined by qPCR. Anta, samples
transfected with antagomir; NC, samples transfected with negative control to
antigomir; hr, hours after transfection. Double, transfection twice of the antagomir and
the time points were taken after the second transfection. Sample numbers are noted at
the left of each name. Red numbers indicate downregulation. B. SEL1L protein
expression determined by Western blotting. Sample numbers are the same as those in
panel A.
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SEL1L protein expression was downregulated after transfection of hsa-mir-155
precursor in MDAPanc3 cells
Both MDAPanc3 and Miapaca2 cells have a very low expression level of hsamir-155 and hsa-mir-223. The expression levels of these 2 miRNAs were assessed
after the transfection of the miRNA precursors using qPCR. As shown in Figure 20,
the expression level of the miRNA markedly increased after transfection of the
precursor when compared to the negative control (> 1000 folds). The endogenous
control RNU6B exhibited similar expression levels for all the samples indicating that
there was a similar amount of the initial cDNA.
The qPCR results in Figure 21A revealed that the expression level of SEL1L
mRNA did not change even though hsa-mir-155 and hsa-mir-223 were overexpressed.
However, from the Western blotting results in Figure 21B and 21C, it was determined
that when hsa-mir-155 was overexpressed in MDAPanc3 cells the SEL1L protein
displayed decreased expression level. When hsa-mir-223 alone was overexpressed, no
significant changes were observed in SEL1L protein expression. When the precursors
were transfected into Miapaca2 cells, there were no detectable changes in SEL1L
expression levels (Figure 22).
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Figure 20. Representative qPCR amplification plot of miRNA expression after
precursor transfection.
An increase in fluorescence indicates the detection of accumulated PCR product.
Quantitation of the amount of target is measured by cycle number. The higher the
initial amount of target cDNA, the sooner accumulated product is detected in the PCR
process, and the lower the cycle number. Curve 1, detection of miRNA in sample
transfected with miRNA precursor; curve 2, detection of miRNA in sample transfected
with negative control to the precursor; curve 3, detection of RNU6B in both samples.
All measurements were duplicated.
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Figure 21. Expression of SEL1L after transfection of hsa-mir-155 and hsa-mir223 precursors in MDAPanc3 cells.
A. Relative quantities of SEL1L mRNA determined by qPCR. Pre, samples transfected
with miRNA precursor; NC, samples transfected with negative control to miRNA
precursors; hr, hours after transfection. B, C. SEL1L protein expression determined by
Western blotting.
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Figure 22. Expression of SEL1L after transfection of hsa-mir-155 and hsa-mir223 precursors in Miapaca2 cells.
A. Relative quantities of SEL1L mRNA determined by qPCR. Pre, samples transfected
with miRNA precursor; NC, samples transfected with negative control to miRNA
precursors; hr, hours after transfection. B, C. SEL1L protein expression determined by
Western blotting.
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Sixteen proteins showed expression level changes after transfection of mir-155
precursor in MDAPanc3 cells
Reverse phase protein assay (RPPA) was applied to measure the transient
response of the MDAPanc3 PDAC cells to the overexpression of hsa-mir-155.
MDAPanc3 cells were transfected with hsa-mir-155 precursor or negative control and
were collected after 48 hours and 72 hours, and then analyzed by RPPA. The
expression levels of 12 proteins assessed were found to be downregulated and 4 were
upregulated. Among these, 6 phosphorylation state-specific antibodies assessed
phosphorylation at specific sites of target proteins. The relative quantities of these
proteins are listed in Table 6A. All other proteins that were analyzed by RPPA did not
show expression alterations and are listed in Table 6B. Through a search of the
microRNA.org resource, it was determined that only the kinase insert domain receptor
(KDR), epidermal growth factor receptor (EGFR), and v-rel reticuloendotheliosis viral
oncogene homolog A (RELA) genes in Table 6Ahad potential binding sites to hsa-mir155, therefore only these three genes would be expected to be downregulated by the
overexpression of hsa-mir-155. This indicated that most of the protein expression
changes were possibly induced through cellular networks instead of direct regulation
by hsa-mir-155.
The data in Table 6A along with SEL1L protein expression data assessed by
Western blotting were then uploaded to the IPA program. Through the use of IPA, 5
canonical pathways were found to be significantly associated with this data set,
including pancreatic adenocarcinoma signaling and PTEN signaling (Table 7A). The
three top involved networks were generated through the use of IPA and are
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summarized in Table 7B. SEL1L was shown to be associated with a network which
functions in cell death, gene expression and organismal development. Another
downregulated protein, ERCC1, was shown to be in the same network.
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4.4 Discussion
In this study, aberrantly upregulated miRNAs in PDAC were studied to
determine if they are involved in the downregulation of SEL1L. The miRNA target
prediction tools helped in the selection of the miRNAs that potentially target SEL1L.
However, the pairing match between a miRNA and a gene is not the only factor that
influences the ability of a miRNA to bind and repress a target gene. Other
characteristics, such as the binding position in the UTR, the flanking sequences, and
mRNA secondary structures, are also important factors in predicting whether a
miRNA is likely to repress the expression of a target gene [105]. Therefore, statistical
methods were used to assess the probability that these 7 miRNAs target and repress
SEL1L gene expression.
A significant correlation was observed between the expression of SEL1L
mRNA and 3 of the 7 miRNAs that had potential binding sites for SEL1L. The
expression of these 3 miRNAs (hsa-mir-143, hsa-mir-155, and hsa-mir-223) was
found to be inversely associated with SEL1L mRNA expression in a high proportion
of PDAC tumors, indicating that these miRNAs possibly repress the expression of
SEL1L in some of the PDAC tumors.
Other investigators have shown that multiple coexpressed miRNAs can target a
single mRNA and work together to repress the gene expression [106-108]. Velu et al.
have recently demonstrated that two miRNAs, miR-21 and miR-196b, work
synergistically in Lin- bone marrow cells to increase the blocking of granulopoiesis
[105]. Similarly, the data presented here demonstrated that the overexpression of an
increasing number of functional miRNAs in PDAC is associated with an increasing
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repression of SEL1L mRNA expression. This statistical result suggests that the 3
miRNAs may work cooperatively to regulate SEL1L expression.
Although hsa-mir-143, hsa-mir-155 and hsa-mir-223 are located on different
chromosomes, a significant pairwise correlation between their expression profiles was
observed. These results suggest that the deregulation of the 3 miRNAs may be caused
by the same mechanism, such as mutant transcription factors that can bind to (or fail to
bind to) the putative regulatory motifs that all 3 miRNA genes have in common [109].
Discovering and understanding the common regulatory mechanisms involved could
provide new insight into the molecular mechanisms underlying pancreatic
tumorigenesis.
A recent publication in Nature demonstrated that for miRNA regulatory
interactions, more than 84% of the lowered protein production was associated with
decreased mRNA levels [110]. The results indicated that destabilization of target
mRNAs is the predominant impact of miRNAs on gene expression. In this study, the
direct correlation between the expression of SEL1L mRNA and SEL1L protein also
suggests that mRNA abundance is a key modulator for SEL1L protein expression in
PDAC. For the small proportion of samples in which mRNA and protein expression
were not correlated (20%), other mechanisms may be involved in regulation of SEL1L
protein expression. Because many mechanisms affect protein levels at both the
translational and the post-translational level, the disagreement in this small proportion
of samples is not surprising [111].
Correlation between two variables does not imply that one directly causes the
other, but it suggests a possible avenue warranting further investigation. In this study,
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the statistical analysis results provided the rationale for conducting further in vivo
functional analysis to explore the role of specific miRNAs in the regulation of SEL1L
expression. Luciferease reporter assays, miRNA inhibition and overexpression
experiments were performed to determine the relationship between SEL1L expression
and the miRNAs from different aspects. Luciferase reporter assays are a method to
determine if a miRNA truly binds to a predicted binding site in a gene. Through either
miRNA inhibition or overexpression, it can be determined whether a miRNA causes a
change in expression levels of a target gene.
It is hypothesized that in a cell line with high expression level of the miRNA,
the reporter expression of vector containing the binding site would be repressed. In
PL18 cells which have a relatively high expression level of hsa-mir-155, a significant
decrease in luciferase expression was observed when comparing the experimental
vector transfection to the results of empty vector transfection. There was no such
decrease observed in MDAPanc3 cells which have a relatively low expression level of
hsa-mir-155. These results suggest that hsa-mir-155 does bind to the predicted binding
site in SEL1L gene. However, the possibility that this result reflected a difference
between different cell lines cannot be ruled out.
Although BxPC3 has a high expression level of both hsa-mir-155 and hsa-mir223, a decrease in luciferase expression was not detected when the cells were
transfected with the experimental vector. This assay did not exhibit the expected result
probably because of the low transfection efficiency in this cell line.
The cotransfection of luciferase vectors and miRNA precursors in 293T cells
also did not show the expected results. One explanation for this result is that hsa-mir-
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155 and hsa-mir-223 do not bind to the predicted binding sites. However, there are
several possible reasons that may have caused a failure of this experiment. First, the
miRNA precursors in this study do not contain a SV40 origin of replication; therefore,
high transfection efficiency of the precusors would not be guaranteed, and it is
possible that the plasmid and a precursor molecule were not transfected into the same
cell. Second, after transfection a high rate of cell death was observed. The dead cells
were removed after the PBS wash. The surviving cells examined by the luciferase
assay may not be good representatives for the co-transfection.
For the miRNA knockdown experiments, it is hypothesized that inhibiting hsamir-155 and hsa-mir-223 would restore the expression of endogenous SEL1L. The
qPCR results revealed that hsa-mir-155 was successfully downregulated by the
antagomir, but the inhibition of hsa-mir-223 did not work for some unknown reason.
A significant increase in SEL1L expression was not detected at either the
mRNA level or the protein level in the 3 PDAC cell lines, even though hsa-mir-155
was inhibited. Maybe hsa-mir-155 is not a modulator of SEL1L and this is the
simplest explanation for these results. However, there are some other possibilities that
should also be considered: (1) there is a delay of SEL1L expression change in
response to the miRNA downregulation, and transient transfection may not reflect the
delayed response; (2) the 2 to 4-fold reduction of hsa-mir-155 is not sufficient to cause
a detectable change in SEL1L expression in these experiments; i.e. SEL1L expression
might have been upregulated but it was not significant enough to be detected; (3) none
of the 3 cell lines used in this study showed low expression of SEL1L and therefore,
they may not serve as ideal models to use for examining regulation of SEL1L gene
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expression. Another possibility is that more than one miRNA is required and this was
not achieved under these experimental conditions.
When either hsa-mir-155 or hsa-mir-223 was overexpressed, it was
hypothesized that the SEL1L gene would be downregulated. A decrease in expression
of SEL1L protein was observed when the precursor of hsa-mir-155 was transfected in
MDAPanc3 cells, either alone or with hsa-mir-223. When the precursor of hsa-mir223 was transfected alone, a detectable downmodulation of SEL1L was not observed
in either cell line. These results provided evidence that hsa-mir-155 is a suppressor of
SEL1L, and hsa-mir-223 is not.
Unlike in PDAC tumors, in the cells where SEL1L protein expression was
decreased there was no corresponding mRNA decrease. Larsson et al. found that
transcripts with high turnover rates are less affected by miRNA overexpression after
transfection [112]. This may be the explanation for the results that SEL1L mRNA
perhaps has a high turnover rate and the expression level of the mRNA was not
significantly affected by the transient transfection of hsa-mir-155.
MDAPanc3 cell line was established in my adviser (Dr. Frazier)’s laboratory,
from a liver metastasis of PDAC [113], whereas Miapaca2 was derived from a grade
G3 primary PDAC tumor [114]. Using Spectral Karyotyping, Sirivatanauksorn et al
showed that these two cell lines had different cytogenetic aberrations [115]. Because
of the different histological and genetic background, it is not a surprise that the results
from these two cell lines are different. The interaction between hsa-mir-155 and
SEL1L might be interrupted in Miapaca2 cells by unknown factors not found in
MDAPanc3. Another possibility is that the interaction reflects an indirect interaction
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in which the overexpressed hsa-mir-155 regulated SEL1L expression through certain
signaling pathways in MDAPanc3 cells, and these pathways might be disrupted in
Miapaca2 cells.
In conclusion, the functional analysis revealed that in the tested PDAC cell
lines hsa-mir-223 did not act as a suppressor of SEL1L; hsa-mir-155 acted as a
suppressor of SEL1L but only under some cellular environments, which could be the
specific genetic background of the cell lines.
Hsa-miR-155 has been reported to be involved in various biological processes,
such as haematopoiesis, inflammation and immunity. It plays an oncogenic role in the
pathogenesis of numerous cancers, including leukemia, breast cancer, colon cancer,
lung cancer, and PDAC [116, 117]. Dr. Sen’s group found elevated expression levels
of hsa-mir-155 in the plasma of PDAC patients as compared with plasma from healthy
controls, suggesting that this miRNA may serve as a blood-based biomarker for the
detection of PDAC [118]. This miRNA has also been reported as a biomarker of early
pancreatic neoplasia [119].
In this study, using RPPA and IPA the evidence suggested that hsa-mir-155
may impact the progression of PDAC not only through direct regulation of target
genes, but also through a series of pathways and networks. Interestingly, several very
important signaling pathways in PDAC were shown to be influenced by hsa-mir-155
modulation in PDAC cell lines. Due to the limited number of validated antibodies in
the RPPA experiment, not all genes that were affected by the upregulation of this
miRNA could be detected. To validate the RPPA data, the variations of the protein
expression need to be confirmed by Western blotting in future studies.
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In conclusion, this study combined statistical analysis with biological
approaches to determine the relationships between several miRNAs and the SEL1L
gene. The finding that the expression of tumor suppressor SEL1L was repressed by the
upregulation of hsa-mir-155 elucidated the mechanism for SEL1L downregulation in
some PDAC cases. The findings provided evidence for using miRNAs as new
approaches for the detection, prevention and treatment of this dismal disease.
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SUMMARY AND FUTURE DIRECTIONS

In this study, the aberrations of the putative tumor suppressor gene SEL1L in
PDAC tumors were investigated. The goal was to determine the mechanism(s) of
SEL1L downregulation. SEL1L downregulation was confirmed in a significant
proportion of the tumors at both mRNA level and protein level. For the first time,
abundant presence of variant splicing products of SEL1L were observed in PDAC, and
for the first time LOH was detected in the SEL1L gene in 15.4% of the tumors. It was
determined that mutations, LOH and promoter methylation are not the mechanisms of
SEL1L downregulation. Data was generated demonstrating that overexpression of hsamir-155 may cause SEL1L downregulation in some PDAC cases. It is possible that
some other miRNAs that were not included in this study may target and repress SEL1L
expression. No mutations were detected in the SEL1L coding region. As tumor
suppressor genes generally follow the “two-hit hypothesis” [120], which implies that
cancer is the result of accumulated mutations to a cell's DNA, although SEL1L has
functions involving tumor suppression it cannot be identified as a classical tumor
suppressor gene.
The findings of the studies described in this thesis provide a better
understanding of the abnormalities of the SEL1L gene in PDAC, which could lead to
new approaches for the early detection, prevention and treatment of this dismal
disease. Through these studies, besides having learned new techniques, I have
expanded my knowledge and experience in problem solving, critical thinking and data
analysis, as well as connecting laboratory findings to clinical information. However,
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there are still many questions that remain as a result of my studies that lead to future
studies.
For the finding of variant splicing products of SEL1L, at this point it is not
clear if these products are specifically associated with PDAC tumors since they were
also observed in normal-appearing adjacent tissues. However, normal appearing tissue
adjacent to the cancer in general is not normal even though the histological appearance
may be normal. The “normal” tissues may display biomarkers that are found in the
tumor due to underlying genetic events that they share with the tumor, but do not
display all of the molecular features that the cancer has. This is called a field effect
and has recently been reviewed by Chai and Brown [121]. As discussed in Chapter 1,
to determine whether there are tumor-specific SEL1L transcripts in PDAC, further
tests with microdissected tissues and deep sequencing are necessary. As mentioned
above in Chapter 1, mis-splicing similar to what we have observed has been reported
for other genes. So far, there is no reported explanation for this mis-splicing
phenomenon. Future studies could examine several PDAC cell lines using RT-PCR
and subcloning to see whether variant transcripts of SEL1L mRNA can be detected.
This might allow us to determine if the variant transcripts arise clonally. If higher
frequency of variant transcripts is observed in the PDAC cells than in the HPNE cells,
DNA microarray could be performed to determine whether there are expression
alterations in splicing machinery-related genes in the PDAC cells when compared to
HPNE cells. If altered splicing machinery-related genes are identified, the next step
would be to restore the normal expression of the gene and determine whether SEL1L
splicing becomes normal.
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In this study, it was determined that overexpression of hsa-mir-155 may be one
of the factors that repress SEL1L expression, but it does not explain the abnormal
expression of SEL1L in all of the PDAC samples. During the past several years, the
miRNA databases have been expanding and many newly discovered miRNAs were
not included in this study. Therefore it is possible that there are other miRNAs
regulating SEL1L expression that we did not test. Also there are some other
mechanisms of gene downregulation that were not studied. These should be
investigated in the future, such as histone modification [122, 123] and pseudogene
silencing [124-126].
Another path of investigation of the SEL1L gene that might shed light on its
role in pancreatic cancer is its association with other known signaling pathways.
Overexpression of SEL1L in human PDAC cells increased the expression levels of
Smad4, activin A, TIMP and PTEN, suggesting an interaction of SEL1L with the
TGFβ and PTEN signaling pathways [30, 33]. The RPPA data presented in this thesis
and IPA analysis indicate a possible interaction of SEL1L with the proteins in the “cell
death, gene expression, organismal development” network. However, the RPPA
results still need to be confirmed by Western analysis, and the most informative
approach to pursue the elaboration of pathways that are influenced by SEL1L would
be to develop a pancreas-specific knock-out mouse model. Using this kind of model, it
would be possible to determine whether the mice develop pancreatic cancer, and
whether the reported signaling pathways and networks are truly influenced. Some
physiological conditions, such as glucose starvation or hypoxia, may need to be
applied for the activation of the UPR/ERAD pathway. Since there are two distinct
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directions of the UPR/ERAD pathway, the stimulation of this pathway should be
quantitatively adjusted to control the amount of generated unfolded/misfolded
proteins.
Hopefully on the basis of the studies described in this thesis, future studies will
build upon these findings in order to understand the pathogenesis of PDAC, and the
further characterization of biomarkers for early detection and prevention of PDAC.
This will put us one step closer to defeating this devastating disease.
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